Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE Umbrella Trial in Refractory TNBC
NCT03805399Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyrotinib, rezvilutamide, dalpiciclib, zeprumetostat, camrelizumab and 4 more in triple-negative breast cancer (TNBC) (11 arms), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
pyrotinibrezvilutamidedalpiciclibzeprumetostatcamrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03805399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805399.